B J Marais1, Susan van Zyl, H S Schaaf, M van Aardt, R P Gie, N Beyers. 1. Desmond Tutu TB Centre and Department of Paediatrics and Child Health, Tygerberg Children's Hospital, Stellenbosch University, Cape Town, South Africa. bjmarais @sun.ac.za
Abstract
BACKGROUND: Current international guidelines recommend 6-9 months of isoniazid (INH) preventive chemotherapy to prevent the development of active tuberculosis in children exposed to a susceptible strain of M tuberculosis. However, this is dependent on good adherence and retrospective studies have indicated that adherence to unsupervised INH preventive chemotherapy is poor. AIM: To prospectively document adherence to six months of unsupervised INH monotherapy and outcome in children with household exposure to an adult pulmonary tuberculosis index case. METHODS: From February 2003 to January 2005 in two suburbs of Cape Town, South Africa, all children <5 years old in household contact with an adult pulmonary tuberculosis index case were screened for tuberculosis and given unsupervised INH preventive chemotherapy once active tuberculosis was excluded. Adherence and outcome were monitored. RESULTS: In total, 217 index cases from 185 households were identified; 274 children <5 years old experienced household exposure, of whom 229 (84%) were fully evaluated. Thirty eight children were treated for tuberculosis and 180 received preventive chemotherapy. Of the children who received preventive chemotherapy, 36/180 (20%) completed > or =5 months of unsupervised INH monotherapy. During the subsequent surveillance period six children developed tuberculosis: two received no preventive chemotherapy, and four had very poor adherence. CONCLUSION: Adherence to six months of unsupervised INH preventive chemotherapy was poor. Strategies to improve adherence, such as using shorter duration multidrug regimens and/or supervision of preventive treatment require further evaluation, particularly in children who are at high risk to progress to disease following exposure.
BACKGROUND: Current international guidelines recommend 6-9 months of isoniazid (INH) preventive chemotherapy to prevent the development of active tuberculosis in children exposed to a susceptible strain of M tuberculosis. However, this is dependent on good adherence and retrospective studies have indicated that adherence to unsupervised INH preventive chemotherapy is poor. AIM: To prospectively document adherence to six months of unsupervised INH monotherapy and outcome in children with household exposure to an adult pulmonary tuberculosis index case. METHODS: From February 2003 to January 2005 in two suburbs of Cape Town, South Africa, all children <5 years old in household contact with an adult pulmonary tuberculosis index case were screened for tuberculosis and given unsupervised INH preventive chemotherapy once active tuberculosis was excluded. Adherence and outcome were monitored. RESULTS: In total, 217 index cases from 185 households were identified; 274 children <5 years old experienced household exposure, of whom 229 (84%) were fully evaluated. Thirty eight children were treated for tuberculosis and 180 received preventive chemotherapy. Of the children who received preventive chemotherapy, 36/180 (20%) completed > or =5 months of unsupervised INH monotherapy. During the subsequent surveillance period six children developed tuberculosis: two received no preventive chemotherapy, and four had very poor adherence. CONCLUSION: Adherence to six months of unsupervised INH preventive chemotherapy was poor. Strategies to improve adherence, such as using shorter duration multidrug regimens and/or supervision of preventive treatment require further evaluation, particularly in children who are at high risk to progress to disease following exposure.
Authors: Mary R Reichler; Randall Reves; Sarah Bur; Josie Ford; Virginia Thompson; Bonita Mangura; Ida M Onorato; Sarah E Valway Journal: South Med J Date: 2002-04 Impact factor: 0.954
Authors: N J M Claessens; F F Gausi; S Meijnen; M M Weismuller; F M Salaniponi; A D Harries Journal: Int J Tuberc Lung Dis Date: 2002-04 Impact factor: 2.373
Authors: B J Marais; R P Gie; H S Schaaf; A C Hesseling; C C Obihara; J J Starke; D A Enarson; P R Donald; N Beyers Journal: Int J Tuberc Lung Dis Date: 2004-04 Impact factor: 2.373
Authors: Suzanne Verver; Robin M Warren; Zahn Munch; Madalene Richardson; Gian D van der Spuy; Martien W Borgdorff; Marcel A Behr; Nulda Beyers; Paul D van Helden Journal: Lancet Date: 2004-01-17 Impact factor: 79.321
Authors: B J Marais; R P Gie; H S Schaaf; A C Hesseling; C C Obihara; L J Nelson; D A Enarson; P R Donald; N Beyers Journal: Int J Tuberc Lung Dis Date: 2004-03 Impact factor: 2.373
Authors: H S Schaaf; I A Michaelis; M Richardson; C N Booysen; R P Gie; R Warren; P D van Helden; N Beyers Journal: Int J Tuberc Lung Dis Date: 2003-05 Impact factor: 2.373
Authors: Merrin E Rutherford; Rovina Ruslami; Melissa Anselmo; Bachti Alisjahbana; Neti Yulianti; Hedy Sampurno; Reinout van Crevel; Philip C Hill Journal: Bull World Health Organ Date: 2013-09-10 Impact factor: 9.408
Authors: Larissa Otero; Tullia Battaglioli; Julia Ríos; Zayda De la Torre; Nayda Trocones; Cielo Ordoñez; Carlos Seas; Patrick Van der Stuyft Journal: Trop Med Int Health Date: 2019-12-12 Impact factor: 2.622
Authors: Stanzi M le Roux; Mark F Cotton; Jonathan E Golub; David M le Roux; Lesley Workman; Heather J Zar Journal: BMC Med Date: 2009-11-03 Impact factor: 8.775